Clinical Roundup Wellcome Sanger Institute: New genetic target for blood cancer treatment April 30, 2021Vol.47 No.17
Drugs & Targets Zynlonta receives FDA accelerated approval for large B-cell lymphoma April 30, 2021Vol.47 No.17
Drugs & Targets Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy April 30, 2021Vol.47 No.17
Drugs & Targets Mobocertinib NDA receives FDA Priority Review as treatment for EGFR Exon20 insertion+ metastatic NSCLC April 30, 2021Vol.47 No.17
Drugs & Targets Onureg receives Positive CHMP Opinion as frontline oral maintenance therapy for adults with AML in first remission April 30, 2021Vol.47 No.17
Drugs & Targets CHMP recommends approval for selumetinib in the EU as first medicine for pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas April 30, 2021Vol.47 No.17
Drugs & Targets European Commission approves GSK’s Jemperli, the first anti-PD-1 therapy approved for recurrent or advanced endometrial cancer April 30, 2021Vol.47 No.17
Drugs & Targets Inivata, Agendia sign agreement for commercialization of RaDaR MRD liquid biopsy assay in breast cancer April 30, 2021Vol.47 No.17
COVID-19 & Cancer Herd immunity is achievable, but it will be tight, Francis Collins, other AACR panelists say April 23, 2021Vol.47 No.16By Alexandria Carolan
In Brief Taofeek K. Owonikoko named chief of Hematology/Oncology at UPMC Hillman April 23, 2021Vol.47 No.16
